Vima LLC’s Arcutis Biotherapeutics ARQT Stock Holding History

Vima LLC’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,000	Closed	-$9.69K	–	451
2023 Q4	$9.69K	Buy	+3,000	New	+$8.15K	0.02%	248

Other funds holding ARQT

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Vima LLC's ARQT Position: Q1 2024 in Review

Vima LLC sold out of Arcutis Biotherapeutics (ARQT) in Q1 2024, closing a stake of 3,000 shares — an estimated $9.69K sold.

Vima LLC first reported a position in ARQT in Q4 2023 and held it in 1 quarter. The position peaked at $9.69K in Q4 2023. 168 funds tracked by Wall St. Rank hold ARQT as of Q1 2024.

Vima LLC reported no remaining Arcutis Biotherapeutics position as of Q1 2024 after selling out during the quarter.
Vima LLC sold 3,000 Arcutis Biotherapeutics shares in Q1 2024, an estimated $9.69K.
Vima LLC first reported a position in Arcutis Biotherapeutics in Q4 2023 and held it in 1 quarter.
Vima LLC's Arcutis Biotherapeutics position peaked at $9.69K in Q4 2023.
168 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2024.

Based on Vima LLC's 13F filing for Q1 2024, filed 17 May 2024.